Last reviewed · How we verify
S-8184 Paclitaxel Injectable Emulsion
At a glance
| Generic name | S-8184 Paclitaxel Injectable Emulsion |
|---|---|
| Sponsor | Achieve Life Sciences |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer (PHASE2)
- Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma (PHASE2)
- Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium (PHASE2)
- Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer (PHASE2)
- Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer (PHASE2)
- TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-8184 Paclitaxel Injectable Emulsion CI brief — competitive landscape report
- S-8184 Paclitaxel Injectable Emulsion updates RSS · CI watch RSS
- Achieve Life Sciences portfolio CI